Annovis Bio Appoints New Principal Financial Officer

An update from Annovis Bio ( (ANVS) ) is now available.

On May 9, 2025, Annovis Bio‘s Board of Directors appointed Andrew Walsh as the Principal Financial Officer, marking a significant change in their financial leadership. In the first quarter of 2025, Annovis initiated a pivotal Phase 3 clinical trial for early Alzheimer’s disease, aiming to enroll 760 participants to evaluate the effects of buntanetap. The company also reported financial results, showing increased cash reserves and a reduction in research and development expenses compared to the previous year.

The most recent analyst rating on (ANVS) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Annovis Bio stock, see the ANVS Stock Forecast page.

Spark’s Take on ANVS Stock

According to Spark, TipRanks’ AI Analyst, ANVS is a Underperform.

Annovis Bio’s overall stock score reflects significant financial challenges with zero revenue and consistent losses, offset slightly by a debt-free balance sheet. Technical indicators suggest a bearish outlook, and valuation metrics are unattractive. Corporate events create a mixed picture, with regulatory compliance issues countered by progress in drug development. The stock remains speculative, relying heavily on future R&D success.

To see Spark’s full report on ANVS stock, click here.

More about Annovis Bio

Annovis Bio Inc., headquartered in Malvern, Pennsylvania, is a late-stage clinical drug platform company focused on developing transformative therapies for neurodegenerative diseases such as Alzheimer’s and Parkinson’s diseases. The company is committed to improving patient outcomes and quality of life through innovative treatments.

Average Trading Volume: 386,466

Technical Sentiment Signal: Sell

Current Market Cap: $30.2M

For a thorough assessment of ANVS stock, go to TipRanks’ Stock Analysis page.